Diabetic retinopathy (DR) is a sight-threatening complication of diabetes and the main cause of blindness in the United States among working adults. Initially, DR progresses as a non-proliferative DR (NPDR) which leads to blinding proliferative DR (PDR). Nearly all people with Type 1 Diabetes (T1D) undergo gradual vision loss over a 20-year period of diabetes, and about 2030% of them progress to the advanced blinding stage of the disease, PDR.
Tight glycaemic management lowers the risk of complications, yet, many diabetic patients develop DR, despite having good glycaemic control. Furthermore, there is no cure or a preventive measure to block PDR. Only recently, over the past decade, with the advent of medicines that block the actions of the vascular endothelial growth factor (VEGF), has considerable progress been made in therapeutic options for PDR.
Nevertheless, not all patients achieve a satisfactory response and many of responders experience frequent invasive intravitreal injections and off-target effects, including increased risk of neuronal toxicity and geographic atrophy. While additional molecular targets, including the plasma kallikrein pathway, lipoprotein-associated phospholipase A2 (Lp-PLA2) and Tie-2, have been identified, with some being clinically evaluated, a critical gap still remains ineffective treatments.
Evidence suggests that targeting DR in the earlier stages, such as mild to moderate NPDR, before permanent damage occurs, would provide long-term benefit. In recent years, our research has focused on the molecular mechanisms of early DR including retinal oxidative stress, mitochondrial dysfunction, mitophagy, inflammation, and premature cell death in diabetes using both in vitro retinal cell cultures and in vivo diabetic rodent models.
Intriguingly, we have discovered a protein called thioredoxin-interacting protein (TXNIP) is strongly induced by diabetes in early DR where it is responsible for mediating cellular oxidative stress, mitophagy, inflammation and premature cell death. Knockdown of TXNIP by intravitreal injection of TXNIP shRNA prevents early molecular defects seen in DR. TXNIP binds to and inhibits the anti-oxidant and thiol-reducing capacity of thioredoxins (Trx) causing cellular redox imbalance and oxidative stress. Trx1 is present in the cytosol and nucleus while Trx2 is located in the mitochondrion. TXNIP is observed in all cellular compartments. Therefore, targeting TXNIP itself or downstream pathways could prevent or slow down the progression of early DR (NPDR) and hence PDR.
Currently, no clinically used, professional TXNIP inhibitors exist; however, several FDA-approved medicines have been reported to interfere with TXNIP pathway, but none of them has been used to treat DR. These drugs include amlexanox, tranilast, and romidepsin and they have been extensively studied for their efficacy, toxicity and safety. This consequently leads to saving time and money and may accelerate their entry to experimental clinical trials centred on targeting an over-activated TXNIP system to arrest DR away from their initial use.
Amlexanox is an inhibitor of TANK-Binding Kinase 1 (TBK1), which phosphorylates mitophagy adaptor optineurin and regulates mitophagic flux to lysosomes. In addition, TBK1 also phosphorylates interferon responsive factor 3 (IRF3) and mediates Type 1 interferon expression and inflammation. Tranilast has been shown to inhibit TXNIP and Nod-like NLRP3 inflammasome; therefore, it may help in preventing cellular oxidative stress and innate immune responses.
Therefore, a combination therapy using amlexanox and tranilast may prove to be effective in preventing or slowing down the progression of DR. Recently, we also demonstrated that a combination therapy of SS-31 (a mitochondria-targeted anti-oxidant), amlexanox and tranilast prevents auranofin-induced redox stress, mitochondrial-lysosomal axis dysregulation and proinflammatory pyroptotic cell death in retinal pigment epithelial cells, suggesting that combination therapies may be more effective than a single drug therapy.
In addition to drug treatment, gene therapy using a TXNIP promoter linked with a neuroprotective factor or an anti-oxidant gene may also be a potential approach for DR treatment. This is because the TXNIP promoter is strongly induced by hyperglycaemia in retinal cells in culture and in diabetic rodent retinas, but not under physiological glucose levels. In addition, the TXNIP promoter is also activated significantly by histone deacetylase inhibitors (HDACi), including suberoylanilide hydroxamic acid (SAHA) or romidepsin.
Therefore, HDACi and TXNIP-promoter gene therapy may also be incorporated in DR therapy for retinal neuroprotective gene expression, which could include pigment epithelium-derived factor (PEDF), glia-derived neurotrophic factor (GDNF), thioredoxin encoded Rod-Derived Cone Viability Factor (RdCVF) and others. These factors are known to be downregulated in DR.
It is currently accepted that neurodegeneration (particularly photoreceptor dysfunction) occurs early in DR before microvascular pathology develops. Therefore, early neuroprotective efforts may constitute a meaningful therapeutical approach to prevent or slow down the progression of late microvascular complications and PDR. Diabetes is a chronic and complex metabolic disease in which PDR develops only after prolonged hyperglycaemic exposure.
Therefore, a window of diabetic duration may exist early to prevent retinal neurovascular dysfunction and progression of PDR; within this time frame, we may devise preventive interventions activating endogenous genes or factors with neuroprotective drugs (preferably orally active drugs) and gene therapy including those mentioned above.
Such a hypothesis is supported by a recent observation, which showed that the expression of retinol binding protein 3 (RBP3), a protein secreted by photoreceptors in the retina, may play a protective role against PDR. RBP3 interacts with glucose transporter Glut1 and reduces excess cellular glucose uptake under hyperglycaemia in diabetics, thus, preventing glucotoxicity in retinal cells including Muller glia and capillary endothelial cells. Those individuals expressing RBP3 do not develop PDR although they have had 50 years of T1D.
In conclusion, new preventive therapies for PDR may be successfully developed by activating endogenous cellular survival mechanisms using drug and gene therapies once a clinical sign of NPDR is observed but before PDR. Such treatments may prevent blindness in diabetic patients.
References
1 Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010 Aug 19;1:e65. PMID: 21364670.
2 Devi TS, Somayajulu M, Kowluru RA, Singh LP. TXNIP regulates mitophagy in retinal Mller cells under high-glucose conditions: implications for diabetic retinopathy. Cell Death Dis. 2017 May 11;8(5):e2777. PMID: 28492550.
3 Lalit PS, Thangal Y, Fayi Y, Takhellambam SD. Potentials of Gene Therapy for Diabetic Retinopathy: The Use of Nucleic Acid Constructs Containing a TXNIP Promoter. Open Access J Ophthalmol. 2018;3(2). PMID: 31106306.
4 Devi TS, Yumnamcha T, Yao F, Somayajulu M, Kowluru RA, Singh LP. TXNIP mediates high glucose-induced mitophagic flux and lysosome enlargement in human retinal pigment epithelial cells. Biol Open. 2019 Apr 25;8(4). PMID: 31023645.
5 Yumnamcha T, Devi TS, Singh LP. Auranofin Mediates Mitochondrial Dysregulation and Inflammatory Cell Death in Human Retinal Pigment Epithelial Cells: Implications of Retinal Neurodegenerative Diseases. Front Neurosci. 2019 Oct 10;13:1065. PMID: 31649499.
6 Yokomizo H, Maeda Y, Park K, Clermont AC, Hernandez SL, et. al., Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med. 2019 Jul 3;11(499). PMID: 31270273.
7 Ibrahim AS, Saleh H, El-Shafey M, Hussein KA, et. al., Targeting of 12/15-Lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis. BBA: Mol Cell Biol Lipids. 2017 Jun;1862(6):636-645. PMID: 28351645.
8 Ibrahim AS, Elshafey S, Sellak H, Hussein KA, El-Sherbiny M, et. al., A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res. 2015 Mar;56(3):599-611. PMID: 25598081.
Funding
NIH/NEI R01 EY023992 (LSP, OVAS).
NIH/NEI core grant P30EY004068 (LDH, OVAS).
Research to Prevent Blindness (MSJ, OVAS).
American Heart Association Grant 18CDA34080403 to ASI.
Please note: This is a commercial profile
Editor's Recommended Articles
Continued here:
Repurposing FDA-approved medicines and gene therapy to combat diabetic retinopathy - Open Access Government
- AI has perfect detection rate for severe cases of condition that causes blindness in preemies - OHSU News - March 10th, 2024
- PulseSight launches with gene therapy platform targeting age-related blindness - Longevity.Technology - March 10th, 2024
- AIOS and RANZCO Unite to Combat Preventable Blindness - Hindustan Times - March 10th, 2024
- Baby born without eyes defies the odds as she thrives despite blindness - Express - March 10th, 2024
- Penn Medicine Accelerator Program to Boost AI-Powered Projects Targeting Blindness and Cervical Cancer - India Education Diary - March 10th, 2024
- Scientists discover gut bacteria`s role in genetically-linked vision loss - WION - February 27th, 2024
- Prevent Blindness launches new Retinopathy of Prematurity Education and Support Program as part of inaugural ... - Modern Retina - February 27th, 2024
- Revolutionizing Eye Disease Treatment: The Unseen Link Between Gut Bacteria and Blindness - Medriva - February 27th, 2024
- The Virtue of Color-Blindness & The End of Race Politics: Arguments for a Colorblind America Book Review - National Review - February 27th, 2024
- Sight loss could be treated by antibiotics after being linked to gut bacteria - The Independent - February 27th, 2024
- Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of ... - PR Web - February 27th, 2024
- $35 million to fight blindness with manufactured corneas | Health Portfolio Ministers | Australian Government ... - Department of Health - February 10th, 2024
- Eye care, vision impairment and blindness - World Health Organization (WHO) - October 27th, 2023
- CHOROIDEREMIA RESEARCH FOUNDATION EXPANDS RESEARCH SUPPORT INTO NONSENSE MUTATIONS OF A RARE INHERITED RETINAL - EIN News - May 1st, 2023
- Chennai eye hospital ties up with Iceland firm to adopt mathematical algorithm to predict diabetic retinopathy - The Hindu - April 23rd, 2023
- Drug-Resistant Bacteria Tied to Eyedrops Can Spread Person to Person ... - April 7th, 2023
- Prevention of Blindness Week 2023: Mumbai experts explain why you should be concerned about glaucoma and the need for regular eye checkups -... - April 7th, 2023
- Childhood blindness - Wikipedia - February 24th, 2023
- FDA Approves Syfovre (pegcetacoplan injection) for the Treatment of ... - February 24th, 2023
- Human mini brains illuminate path to curing blindness - February 16th, 2023
- Raymond V. Gilmartin: Man with a global vision - February 16th, 2023
- Why Are People So Mad About MrBeast's Blindness Video? - February 16th, 2023
- This heartwarming video of a colorblind boy seeing color for the first time will make you cry - Indiatimes.com - February 16th, 2023
- Blindness (Vision Impairment): Types, Causes and Treatment - February 8th, 2023
- CDC urges people to stop using brand of artificial tears linked to ... - February 8th, 2023
- Health News Roundup: U.S. FDA says India-made eye drop linked to some infections, blindness and one death; China records 3,278 COVID-related deaths... - February 8th, 2023
- I had two strokes at 29 and gone blind -I've been accused of faking my sight loss - Daily Mail - February 8th, 2023
- Blindness and vision impairment - World Health Organization - January 23rd, 2023
- Recovery from blindness - Wikipedia - January 23rd, 2023
- Colour blindness tests, juggling, avoiding glare: A hockey goalkeepeers quest to train his biggest weapon, eyes - The Indian Express - January 23rd, 2023
- But Did You See the Gorilla? The Problem With Inattentional Blindness ... - October 15th, 2022
- Canadians unaware of diseases that lead to blindness, survey says - CTV News Northern Ontario - October 15th, 2022
- A Review of Corneal Blindness: Causes and Management - Cureus - October 15th, 2022
- A cure for blindness may be first product made in space - Freethink - October 15th, 2022
- Is MrBeast trying to cure 1000 people's blindness? - indy100 - October 15th, 2022
- Early detection and management is the key to prevent glaucoma related blindness: Experts - Express Healthcare - October 15th, 2022
- As World Sight Day Nears, River Blindness is Fading - SaportaReport - October 15th, 2022
- Tears of happiness: How curing blindness in Dolakha saved a girls future - City A.M. - October 15th, 2022
- World Sight Day: Orbis, UC Davis team up to train eye care teams from Latin America to fight avoidable blindness - Ophthalmology Times - October 15th, 2022
- Juan Williams: The GOPs epidemic of intentional blindness - The Hill - October 15th, 2022
- Charles pays tribute to Malawi's elimination of disease causing blindness - Express & Star - October 15th, 2022
- Coping with calamity: Former NYT columnist Frank Bruni on blindness and vision, at Morristown book fest keynote - Morristown Green - October 15th, 2022
- Sighting solutions in a world of vision for weavers - The New Indian Express - October 15th, 2022
- Blindfold run raises $40,000 for the MUHC Foundation to support glaucoma care at the MUHC - StreetInsider.com - October 15th, 2022
- MacKenzie Scott Donates $15M to Address the Eyecare Needs of the Impoverished - InvisionMag - October 15th, 2022
- Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts -... - September 20th, 2022
- Treating cataracts before 'critical age' imperative FBC News - FBC News - September 20th, 2022
- GenSight Biologics to Present at Upcoming Industry and Investor Conferences - Business Wire - September 20th, 2022
- Ashton Kutcher battled vasculitis causing blindness, loss of hearing. Know all about the rare condition - India TV News - August 11th, 2022
- Prevent Blindness Is Recognized as a Healthy People 2030 Champion for Supporting the Initiative's Vision - Vision Monday - August 11th, 2022
- Researchers make progress toward a stem cellbased therapy for blindness - Ophthalmology Times - August 11th, 2022
- The strategic blindness of Israel's caretaker government - JNS.org - August 11th, 2022
- UND professor carries the torch for UND studies of visual impairment and blindness - Grand Forks Herald - August 11th, 2022
- Karan Nagrani is using social media to raise awareness about the 'spectrum of blindness' - ABC News - August 11th, 2022
- Vision impairment and blindness related to NCDs: Fong - FBC News - August 11th, 2022
- Strategic blindness of caretaker government - The Jewish Star - August 11th, 2022
- Massachusetts woman blinded by attack working to help others regain sight - WCVB Boston - August 11th, 2022
- Persuasion Film Review: Is Heterogeneous Casting Race-Inclusionary Or Escapist? - Feminism In India - August 11th, 2022
- Is It Time To Start Using Race And Gender To Combat Bias In Lending? - Forbes - August 11th, 2022
- The journey of Kali Yugi started with the mistake of objectives! - Youthistaan - August 11th, 2022
- A 50-State Review of Access to State Medicaid Program Information for People with Limited English Proficiency and/or Disabilities Ahead of the PHE... - August 11th, 2022
- iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for... - August 11th, 2022
- Vitamin B12: Why You Need It & Foods To Increase Your Vitamin B12 Intake - NDTV - August 11th, 2022
- Jack Levine: Remembering a dad who proved that even in blindness, there can be vision - The Florida Times-Union - June 26th, 2022
- Potion of Blindness | Minecraft Ideas Wiki | Fandom - June 26th, 2022
- Tightening a molecular "zipper" could help prevent hereditary blindness - New Atlas - June 26th, 2022
- What's the Link Between Glaucoma and Dry Eyes? - Healthline - June 26th, 2022
- Lisa Durden's upcoming documentary "Blind Divas" follows Krystle Allen and Naquela Wright-Prevoe, two Black women entrepreneurs, determined... - June 26th, 2022
- Trump election lies may fit legal concept of willful blindness - Chicago Tribune - June 26th, 2022
- Sightsavers relaunches its thematic strategy The Sun Nigeria - Daily Sun - June 26th, 2022
- Trachoma elimination: millions more to benefit from donated azithromycin - World Health Organization - June 26th, 2022
- Dangers of super gonorrhoea from infertility to blindness as global warning issued - Daily Star - June 26th, 2022
- Fifty years of Title IX: What is it, what does it cover and do we still need it? - The Athletic - June 26th, 2022
- How The SMH Got That Rebel Wilson Story So Wrong - Junkee - June 26th, 2022
- The Week That Was: All of Lawfare in One Post - Lawfare - Lawfare - June 26th, 2022
- Why Brad Pitt quit smoking and drinking altogether during the pandemic - BusinessGhana - June 26th, 2022
- Watch your eye - The New Indian Express - June 26th, 2022
- Olivia Brouwer's art is for everyone to see and touch - Hamilton Spectator - June 26th, 2022
- Monkeypox may not mutate as fast as coronaviruses, but that doesn't mean it can't adapt to its new hosts - The Conversation - June 26th, 2022
- Former American Express Foundation President Takes Helm of Signature Theatre - The Chronicle of Philanthropy - June 26th, 2022